Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Faculty consensus establishes chest CT surveillance every nine weeks for patients receiving trastuzumab deruxtecan, narrowing to six-week intervals for higher-risk patients or during ILD re-challenge. For cardiac monitoring, clinicians obtain a baseline echocardiogram followed by repeat evaluations at least every three months to catch asymptomatic declines in left ventricular ejection fraction.

Related Insights

Contrary to the belief that any interstitial lung disease (ILD) requires permanent discontinuation of TDXD, data shows patients with asymptomatic, radiographically-identified Grade 1 ILD can be safely rechallenged. Treatment is paused and the patient is treated, but therapy can resume once resolved. Symptomatic ILD, however, requires permanent discontinuation.

A practice gap exists in managing side effects of Trastuzumab-Deruxtecan (TDXD) between specialties. Breast oncologists, with more experience, are far more aggressive with prophylactic anti-emetics and frequent imaging to detect asymptomatic ILD. This proactive approach is a key lesson for lung cancer specialists and others now adopting the drug.

For urothelial cancer patients treated with trastuzumab deruxtecan (TDXD), developing symptomatic (Grade 2) interstitial lung disease or pneumonitis is a critical event. Following protocols from other cancers, this requires permanent discontinuation of the therapy. Re-challenging the patient with TDXD after a Grade 2 event is not recommended without more disease-specific safety data.

To manage the risk of interstitial lung disease (ILD) with TDXD, experts now recommend routine screening with high-resolution chest CT scans every 6-12 weeks. This practice aims to catch asymptomatic, grade 1 ILD early, allowing for treatment holds and steroid intervention, which may preserve the option to rechallenge.

Interstitial Lung Disease (ILD) is a significant risk with TDXD. However, a history of a completely resolved grade 1 event does not automatically preclude a patient from receiving the drug again. Clinicians may consider a re-challenge, balancing the risk against the lack of other viable therapies.

While oncologists feel comfortable re-challenging patients after grade 1 asymptomatic radiographic pneumonitis resolves—monitoring them closely with six-week CT scans—they refuse to restart trastuzumab deruxtecan following grade 2 ILD. Current clinical literature lacks sufficient safety evidence to justify retreating grade 2 toxicity, leading clinicians to draw a strict line against restarting therapy.

Adopting T-DXd in early-stage breast cancer requires frequent chest CT scans to monitor for potentially fatal interstitial lung disease (ILD), a practice not standard for current therapies. This presents significant new logistical challenges, including securing insurance approvals, managing patient access, and increasing the overall burden of care.

Interstitial lung disease (ILD) is a serious risk with trastuzumab deruxtecan (TDXD). Oncologists must take it extremely seriously, engaging a pulmonologist immediately at the first sign of symptoms or CT scan findings. A collaborative, multidisciplinary approach is essential for safely managing this potentially fatal toxicity.

The risk of serious interstitial lung disease (ILD) with the drug TDXD is heavily dependent on the total duration of therapy. A short, 4-cycle neoadjuvant course has a low 4% ILD rate, whereas a longer 14-cycle adjuvant course sees this risk more than double to over 10%, making the shorter pre-surgical approach significantly safer.

To proactively screen for interstitial lung disease (ILD), a serious risk with trastuzumab deruxtecan (TDXD), imaging should be conducted more frequently than the typical 12-week interval. The recommended strategy is to scan patients every nine weeks, or after every three cycles, to identify asymptomatic Grade 1 ILD cases early.